Neural basis of Delta-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition.
Stefan Borgwardt, Paul Allen, Sagnik Bhattacharyya, Paolo Fusar‐poli, José A. Crippa, Marc L. Seal, Valter Fraccaro, Zerrin Atakan, Rocío Martín‐Santos, Colin O'Carroll, Katya Rubia, Philip Mcguire
Biological Psychiatry December 1, 2008 DOI: 10.1016/j.biopsych.2008.05.011 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Double-blind, placebo-controlled, repeated measures within-subject experiment Randomized Peer reviewed |
|---|---|
| Sample size | 15 |
| Population | Healthy volunteers |
| Interventions | Delta-9-tetrahydrocannabinol (THC) cannabidiol (CBD) placebo |
| Topics | Cannabis CBD |
| Key findings | THC attenuated activation in the right inferior frontal and anterior cingulate gyri during a motor inhibition task relative to placebo, suggesting reduced engagement of brain regions mediating response inhibition. CBD instead deactivated the left temporal cortex and insula, regions not usually implicated in response inhibition. These effects were unrelated to changes in anxiety, intoxication, sedation, or psychotic symptoms. |
Abstract
This study examined the effect of Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) on brain activation during a motor inhibition task. Functional magnetic resonance imaging and behavioural measures were recorded while 15 healthy volunteers performed a Go/No-Go task following administration of either THC or CBD or placebo in a double-blind, pseudo-randomized, placebo-controlled repeated measures within-subject design. Relative to placebo, THC attenuated activation in the right inferior frontal and the anterior cingulate gyrus. In contrast, CBD deactivated the left temporal cortex and insula. These effects were not related to changes in anxiety, intoxication, sedation, and psychotic symptoms. These data suggest that THC attenuates the engagement of brain regions that mediate response inhibition. CBD modulated function in regions not usually implicated in response inhibition.
Comparable studies
Other randomized controlled trials on CBD, most cited first.
Citations in the library
Cited by 47
- Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life Frontiers in Pharmacology May 11, 2017
- Acute Effects of a Single, Oral dose of d9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) Administration in Healthy Volunteers Current Pharmaceutical Design September 12, 2012
- The neuropsychopharmacology of cannabis: A review of human imaging studies Pharmacology & Therapeutics October 20, 2018
- Neuroimaging in cannabis use: a systematic review of the literature Psychological Medicine July 23, 2009
- Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition Psychopharmacology May 1, 2019
and 42 more in the library
Cites 8
- Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug Brazilian Journal of Medical and Biological Research April 1, 2006
- Disturbances of visual information processing in early states of psychosis and experimental delta-9-tetrahydrocannabinol altered states of consciousness. Schizophrenia Research December 1, 2006
- Neuroimaging of marijuana smokers during inhibitory processing: a pilot investigation. Brain research. Cognitive brain research April 2005
- Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biological Psychiatry March 15, 2005
- The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology August 2004
and 3 more in the library